サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1392752

白血病治療薬の世界市場レポート 2024年

Leukemia Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
白血病治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

白血病治療薬市場規模は近年力強く成長しています。2023年の165億5,000万米ドルから2024年には177億8,000万米ドルへと、CAGR7.4％で拡大します。歴史的な期間に観察された成長は、高齢者人口の増加、白血病の早期発見につながる診断の進歩、白血病有病率の上昇、研究開発への投資の増加、個別化医療アプローチの拡大など、いくつかの要因に起因しています。

2023年の白血病治療薬市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。白血病治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 白血病治療薬市場の特徴

第3章 白血病治療薬市場の動向と戦略

第4章 白血病治療薬市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の白血病治療薬市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年から2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 白血病治療薬市場セグメンテーション

  • 世界の白血病治療薬市場、治療タイプ別セグメンテーション、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで
  • 化学療法
  • 免疫療法
  • 標的療法
  • その他の治療法
  • 世界の白血病治療薬市場、白血病治療別セグメンテーション、実績および予測、2018-2023年、2023-2028F、2033F
  • 急性リンパ性白血病
  • 急性骨髄性白血病
  • 慢性リンパ性白血病
  • 慢性骨髄性白血病
  • 他の種類の白血病
  • 世界の白血病治療薬市場、分子タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028F、2033F
  • 低分子
  • 生物製剤
  • 世界の白血病治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 病院
  • 在宅ケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 白血病治療薬市場の地域および国分析

  • 世界の白血病治療薬市場、地域別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで
  • 世界の白血病治療薬市場、国別、実績および予測、2018年から2023年、2023年から2028年まで、2033年まで

第8章 アジア太平洋の白血病治療薬市場

  • 概要
  • 地域情報、COVID-19症の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第9章 中国の白血病治療薬市場

第10章 インドの白血病治療薬市場

第11章 日本の白血病治療薬市場

第12章 オーストラリアの白血病治療薬市場

第13章 インドネシアの白血病治療薬市場

第14章 韓国の白血病治療薬市場

第15章 西欧の白血病治療薬市場

  • 概要
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第16章 英国の白血病治療薬市場

第17章 ドイツの白血病治療薬市場

第18章 フランスの白血病治療薬市場

第19章 イタリアの白血病治療薬市場

第20章 スペインの白血病治療薬市場

第21章 東欧の白血病治療薬市場

  • 概要
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第22章 ロシアの白血病治療薬市場

第23章 北米の白血病治療薬市場

  • 概要
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第24章 米国の白血病治療薬市場

第25章 カナダの白血病治療薬市場

第26章 南米の白血病治療薬市場

  • 概要
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第27章 ブラジルの白血病治療薬市場

第28章 中東の白血病治療薬市場

  • 概要
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第29章 アフリカの白血病治療薬市場

  • 概要
  • 治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 白血病治療別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第30章 白血病治療薬市場の競合情勢と企業プロファイル

  • 白血病治療薬市場の競合情勢
  • 白血病治療薬市場の企業プロファイル
    • Novartis International AG
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • Sanofi S. A.

第31章 世界の白血病治療薬市場の競合ベンチマーキング

第32章 世界の白血病治療薬市場の競合ダッシュボード

第33章 白血病治療薬市場における主要な合併と買収

第34章 白血病治療薬市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10440

“Leukemia Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leukemia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leukemia therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The leukemia therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment Type: Chemotherapy; Immunotherapy; Targeted Therapy; Other Treatments
  • 2) By Type Of Leukemia: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Other Type Of Leukemia
  • 3) By Molecule Type: Small Molecules; Biologics
  • 4) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Companies Mentioned: Novartis International AG; AbbVie Inc.; Bristol Myers Squibb Company; F. Hoffmann-La Roche AG; Sanofi S. A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Leukemia therapeutics refer to treatments used to address an aggressive malignancy characterized by an excessive presence of myeloblasts, immature white blood cells, in the blood or bone marrow. The choice of treatment for leukemia depends on factors such as age, overall health, the specific type of leukemia, its current state within the body, and other relevant considerations.

The primary types of treatments in leukemia therapeutics include chemotherapy, immunotherapy, targeted therapy, and other specific treatments. Immunotherapy involves stimulating the body's immune system to recognize and eliminate malignant cells. This approach is applied to treat various types of leukemia, including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, using both small molecules and biologics. End users of leukemia therapeutics include hospitals, homecare settings, specialty clinics, and other relevant healthcare providers.

The leukemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry. This leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukemia therapeutics market size has grown strongly in recent years. It will grow from $16. 55 billion in 2023 to $17. 78 billion in 2024 at a compound annual growth rate (CAGR) of 7. 4%. The growth observed during the historic period can be attributed to several factors, including the increase in the geriatric population, advancements in diagnostics leading to early detection of leukemia, a rise in the prevalence of leukemia, growing investments in research and development, and the expansion of personalized medicine approaches.

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $23. 98 billion in 2028 at a compound annual growth rate (CAGR) of 7. 8%. The anticipated growth in the forecast period can be attributed to several factors, including the development of novel immunotherapies for leukemia, a growing focus on precision medicine in leukemia treatment, the expansion of indications for existing leukemia therapies, increased adoption of gene therapies, and advances in supportive care for leukemia patients. Major trends expected in the forecast period include the integration of biomarker-driven approaches, the rise of combination therapies for enhanced efficacy, an emphasis on minimal residual disease monitoring, increasing use of CAR-T cell therapies, and exploration of targeted therapies based on specific leukemia subtypes. These trends collectively contribute to the positive trajectory of the leukemia therapeutics market.

The leukemia therapeutics market is experiencing growth driven by the increasing prevalence of leukemia, a type of blood cancer characterized by uncontrolled blood cell growth originating in the bone marrow. The global accessibility of medical treatment for leukemia patients and the expanding array of treatment options contribute to the growing demand for leukemia therapeutics. As of January 2023, the American Cancer Society projects around 59,610 new cases of leukemia and approximately 23,710 leukemia-related deaths in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and approximately 11,310 AML-related deaths are expected in the same year. Thus, the escalating incidence of leukemia is a significant factor propelling the growth of the leukemia therapeutics market.

The growth of the geriatric population is anticipated to further fuel the expansion of the leukemia therapeutics market. The term 'geriatric population' pertains to individuals aged 65 and older. With the aging of the population, the heightened risk of developing leukemia and related blood disorders increases, leading to a greater demand for leukemia therapeutics. According to a report by the World Health Organization (WHO) in October 2022, it is projected that one in six people globally will be 60 or older by 2030, and by 2050, the worldwide population of individuals aged 60 and older will reach 2. 1 billion. Consequently, the rise in the geriatric population serves as a driving force for the growth of the leukemia therapeutics market.

A new trend gaining traction in the leukemia therapeutics market is the adoption of combination therapies. In combination therapies, two or more treatment modalities are explored, often in conjunction with immunotherapies or targeted therapies, with the goal of delivering long-term survival benefits not achievable through current approaches. For example, in September 2021, the clinical research team at Dana-Farber Cancer Institute reported the effectiveness of a combination therapy involving three molecularly targeted drugs-BCL-2 inhibitor (venetoclax), second-generation BTK inhibitor (acalabrutinib), and CD20 inhibitor (obinutuzumab)-against chronic lymphocytic leukemia (CLL).

Major companies operating in the leukemia therapeutics market are focusing on innovation by developing groundbreaking products such as Chimeric Antigen Receptor T-cell (CAR-T) therapies to expand their customer base, boost sales, and increase revenue. CAR-T therapy represents a revolutionary form of immunotherapy for treating certain types of cancer. In October 2021, Kite Pharma received U. S. Food and Drug Administration (FDA) approval for Tecartus, the first and only CAR-T cell therapy authorized for use in adults aged 18 and above with B-cell precursor acute lymphoblastic leukemia (ALL). Tecartus, an autologous CAR-T therapy targeting CD19, employs the XLP manufacturing process, a critical step in specific B-cell malignancies.

In November 2021, Pfizer Inc. acquired Trillium Therapeutics for approximately $2. 22 billion, enhancing its oncology portfolio with next-generation immunotherapies. Trillium Therapeutics, based in Canada, focuses on developing cancer treatment therapies.

Major companies operating in the in the leukemia therapeutics market report are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Celgene Corporation, Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Trovagene Inc., Akebia Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

North America was the largest region in the leukemia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the leukemia therapeutics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The leukemia therapeutics market includes revenues earned by entities by by killing fast-growing cancer cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Leukemia Therapeutics Market Characteristics

3. Leukemia Therapeutics Market Trends And Strategies

4. Leukemia Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Leukemia Therapeutics Market Size and Growth

  • 5.1. Global Leukemia Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Leukemia Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Leukemia Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Leukemia Therapeutics Market Segmentation

  • 6.1. Global Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Other Treatments
  • 6.2. Global Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Other Type Of Leukemia
  • 6.3. Global Leukemia Therapeutics Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Small Molecules
  • Biologics
  • 6. 4. Global Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users

7. Leukemia Therapeutics Market Regional And Country Analysis

  • 7.1. Global Leukemia Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Leukemia Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Leukemia Therapeutics Market

  • 8.1. Asia-Pacific Leukemia Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8. 4. Asia-Pacific Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Leukemia Therapeutics Market

  • 9.1. China Leukemia Therapeutics Market Overview
  • 9.2. China Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9. 4. China Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Leukemia Therapeutics Market

  • 10.1. India Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Leukemia Therapeutics Market

  • 11.1. Japan Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Leukemia Therapeutics Market

  • 12.1. Australia Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Leukemia Therapeutics Market

  • 13.1. Indonesia Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Leukemia Therapeutics Market

  • 14.1. South Korea Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Leukemia Therapeutics Market

  • 15.1. Western Europe Leukemia Therapeutics Market Overview
  • 15.2. Western Europe Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15. 4. Western Europe Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Leukemia Therapeutics Market

  • 16.1. UK Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Leukemia Therapeutics Market

  • 17.1. Germany Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Leukemia Therapeutics Market

  • 18. 5. France Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 6. France Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 7. France Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Leukemia Therapeutics Market

  • 19. 9. Italy Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Leukemia Therapeutics Market

  • 20.13. Spain Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Leukemia Therapeutics Market

  • 21.1. Eastern Europe Leukemia Therapeutics Market Overview
  • 21.2. Eastern Europe Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21. 4. Eastern Europe Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Leukemia Therapeutics Market

  • 22.1. Russia Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Leukemia Therapeutics Market

  • 23.1. North America Leukemia Therapeutics Market Overview
  • 23.2. North America Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23. 4. North America Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Leukemia Therapeutics Market

  • 24.1. USA Leukemia Therapeutics Market Overview
  • 24.2. USA Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24. 4. USA Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Leukemia Therapeutics Market

  • 25.1. Canada Leukemia Therapeutics Market Overview
  • 25.2. Canada Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25. 4. Canada Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Leukemia Therapeutics Market

  • 26.1. South America Leukemia Therapeutics Market Overview
  • 26.2. South America Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26. 4. South America Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Leukemia Therapeutics Market

  • 27.1. Brazil Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Leukemia Therapeutics Market

  • 28.1. Middle East Leukemia Therapeutics Market Overview
  • 28.2. Middle East Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28. 4. Middle East Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Leukemia Therapeutics Market

  • 29.1. Africa Leukemia Therapeutics Market Overview
  • 29.2. Africa Leukemia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Leukemia Therapeutics Market, Segmentation By Treatment Of Leukemia, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29. 4. Africa Leukemia Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Leukemia Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Leukemia Therapeutics Market Competitive Landscape
  • 30.2. Leukemia Therapeutics Market Company Profiles
    • 30.2.1. Novartis International AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. AbbVie Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. Bristol Myers Squibb Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. F. Hoffmann-La Roche AG
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. Sanofi S. A.
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Leukemia Therapeutics Market Competitive Benchmarking

32. Global Leukemia Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Leukemia Therapeutics Market

34. Leukemia Therapeutics Market Future Outlook and Potential Analysis

  • 34.1 Leukemia Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Leukemia Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Leukemia Therapeutics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer